Global Cord Blood Corporation (DE:6CB)
BERLIN:6CB

Global Cord Blood (DE:6CB) Income Statement

0 Followers

Global Cord Blood Income Statement

Last quarter (Q4 2022), Global Cord Blood's total revenue was ¥297.21M, a decrease of -1.69% from the same quarter last year. In Q4, Global Cord Blood's net income was ¥104.72M. See Global Cord Blood’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Mar 22Mar 21Mar 20Mar 19Mar 18
Total Revenue
¥ 1.24B¥ 1.24B¥ 1.16B¥ 1.22B¥ 986.75M¥ 936.77M
Cost of Revenue
¥ 183.31M¥ 183.31M¥ 178.95M¥ 189.13M¥ 186.03M¥ 181.48M
Gross Profit
¥ 1.06B¥ 1.06B¥ 980.69M¥ 1.03B¥ 800.73M¥ 755.28M
Operating Expense
¥ 451.08M¥ 451.08M¥ 435.82M¥ 473.30M¥ 419.07M¥ 475.42M
Operating Income
¥ 608.87M¥ 608.87M¥ 544.87M¥ 559.03M¥ 381.66M¥ 279.86M
Net Non Operating Interest Income Expense
¥ 32.61M¥ 32.61M¥ 30.90M¥ 25.36M¥ 25.32M¥ 18.68M
Other Income Expense
¥ -13.64M¥ -13.64M¥ 34.98M¥ -5.58M¥ -50.52M¥ 4.99M
Pretax Income
¥ 627.84M¥ 627.84M¥ 610.75M¥ 578.81M¥ 356.46M¥ 303.54M
Tax Provision
¥ 118.35M¥ 118.35M¥ 94.55M¥ 101.08M¥ 61.26M¥ 62.66M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
¥ 501.06M¥ 501.06M¥ 508.25M¥ 470.72M¥ 291.12M¥ 237.10M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
¥ 634.39M¥ 634.39M¥ 614.77M¥ 662.43M¥ 605.10M¥ 656.90M
Net Income From Continuing And Discontinued Operation
¥ 501.06M¥ 501.06M¥ 508.25M¥ 470.72M¥ 291.12M¥ 237.10M
Normalized Income
¥ 516.66M¥ 517.22M¥ 485.58M¥ 481.42M¥ 337.67M¥ 236.49M
Interest Expense
---¥ 0.00¥ 0.00¥ 3.26M
EBIT
¥ 608.87M¥ 608.87M¥ 544.87M¥ 559.03M¥ 356.46M¥ 306.79M
EBITDA
¥ 608.87M¥ 656.79M¥ 593.96M¥ 608.48M¥ 408.83M¥ 357.38M
Currency in CNY

Global Cord Blood Earnings and Revenue History


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis